SCHEMBL161776

SCHEMBL161776

COC(=O)c1cc(O)c2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.56
KDM4E B2RXH2 3/20 0.56
XDH P47989 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
POLB P06746 1/20 0.56
GAA P10253 1/20 0.56
NFKB1 P19838 1/20 0.56
GFER P55789 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
FUT7 Q11130 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
FTO Q9C0B1 1/20 0.56
LCK P06239 1/20 0.55
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669833 0.87 NQO2 (0.46) LMNAKDM4EXDHTDP1POLB
SCHEMBL27364085 0.84 LCK (0.66) LMNAKDM4EXDHTDP1POLB
SCHEMBL7787516 0.84 FTO (0.55) LMNAKDM4EXDHTDP1POLB
SCHEMBL7789715 0.84 LMNA (0.54) LMNAKDM4EXDHTDP1POLB
SCHEMBL161775 0.83 ALDH1A1 (0.50) LMNAKDM4EXDHTDP1POLB
SCHEMBL15936293 0.83 ALDH1A1 (0.58) LMNAKDM4EGAAFTOLCK
SCHEMBL13104720 0.83 ALDH1A1 (0.50) KDM4ETDP1FTOLCKCA12
SCHEMBL163865 0.82 CA12 (0.57) KDM4EGAAL3MBTL1CA12CA1
SCHEMBL161258 0.82 CA12 (0.57) LMNAKDM4EL3MBTL1CA12CA1
SCHEMBL162582 0.82 NQO2 (0.44) GAAFTOLCKCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-04-23 US disclosed
EP-4633738-A1 CYTOTOXIC COMPOUNDS Pheon Therapeutics Ltd (GB) 2025-10-22 EP disclosed
EP-4592295-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-07-30 EP disclosed
EP-4562017-A1 NOVEL ACC INHIBITORS Pfizer Inc. (US) 2025-06-04 EP disclosed
CN-120019059-A Novel ACC inhibitors 辉瑞公司 2025-05-16 CN disclosed
CN-115151551-B Macrocyclic indole derivatives as MCL-1 inhibitors 詹森药业有限公司 2024-10-25 CN disclosed
WO-2024127332-A1 CYTOTOXIC COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2024-06-20 WO disclosed
US-20240190893-A1 MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2024-06-13 US disclosed
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed
WO-2024023727-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-02-01 WO disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2013083991-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY IMPERIAL INNOVATIONS LIMITED (GB) 2013-06-13 WO disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed
US-7807075-B2 Photochromic compositions and light transmissible articles ADVANCED POLYMERIK PTY LTD (AU) 2010-10-05 US disclosed
WO-2009121149-A1 STABILIZED PHOTOCHROMIC ADVANCED POLYMERIK PTY LTD (AU) 2009-10-08 WO disclosed
US-20090093601-A1 Photochromic Compounds Comprising Polymeric Substituents And Methods For Preparation And Use Thereof POLYMERS AUSTRALIA PTY LIMITED (AU) 2009-04-09 US disclosed
US-20080006798-A1 Photochromic Compositions and Light Transmissible Articles JAMES ROBINSON SPECIALITY INGREDIENTS LTD (GB) 2008-01-10 US disclosed
US-20070249794-A1 Photochromic Compositions and Articles Comprising Polyether Oligomer POLYMERS AUSTRALIA PTY LIMITED (AU) 2007-10-25 US disclosed
US-20070187656-A1 Photochromic compositions and articles comprising siloxane, alkylene or substituted alkylene oligomers POLYMERS AUSTRALIA PTY LIMITED (AU) 2007-08-16 US disclosed
US-7247262-B2 Photochromic compositions and light transmissible articles POLYMERS AUSTRALIA PTY LTD. (AU) 2007-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190893-A1 MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER MCL1, BCL9, BCL9L LMNA 1705/4885KDM4E 1220/4885XDH 2717/4885
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, HRAS LMNA 4088/4885KDM4E 4544/4885XDH 2948/4885
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB LMNA 2881/4885KDM4E 4784/4885XDH 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.